Regulation of gene transcription of B lymphoma Mo‑MLV insertion region 1 homolog (Review)
Authors:
Open Access
- 5 April 2021
- journal article
- review article
- Published by Spandidos Publications in Biomedical Reports
- Vol. 14 (6) , 1-8
Abstract
B lymphoma Mo‑MLV insertion region 1 homolog (Bmi‑1) is a core protein component of the polycomb repressive complex 1 that inhibits cell senescence and maintains the self‑renewal ability of stem cells via downregulation of p16Ink4a and p19Arf expression. Bmi‑1 serves an important role in hematopoietic stem cell maintenance and neurodevelopment during embryonic development, and it has been shown to enhance tumorigenesis by promoting cancer stem cell self‑renewal and epithelial to mesenchymal transition. Emerging evidence suggests that Bmi‑1 overexpression is closely related to the development and progression of various types of cancer, and that downregulation of Bmi‑1 expression can inhibit the proliferation, invasion and metastasis of cancer cells. It is therefore important to elucidate the mechanisms underlying the regulation of Bmi‑1 expression both under normal growth conditions and in malignant tissues. In the present review, the current body of knowledge pertaining to the transcriptional and post‑transcriptional regulation of the BMI‑1 gene is discussed, and the potential mechanisms by which Bmi‑1 is dysregulated in various types of cancer are highlighted. Bmi‑1 expression is primarily controlled via transcriptional regulation, and is regulated by the transcription https://www.ushuaia.pl/hyphen/?ln=en factors of the Myc family, including Myb, Twist1, SALL4 and E2F‑1. Post‑transcriptionally, regulation of Bmi‑1 expression is inhibited by several microRNAs and certain small‑molecule drugs. Thus, regulatory transcriptional factors are potential therapeutic targets to reduce Bmi‑1 expression in cancer cells. Thus, the present review provides an up‑to‑date review on the regulation of BMI‑1 gene expression at the transcriptional and post‑transcriptional level.Keywords
This publication has 75 references indexed in Scilit:
- BMI1 Polycomb Group Protein Acts as a Master Switch for Growth and Death of Tumor Cells: Regulates TCF4-Transcriptional Factor-Induced BCL2 SignalingPLOS ONE, 2013
- NVP-LDE-225 (Erismodegib) inhibits epithelial–mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128Oncogenesis, 2013
- miR-200c Inhibits Melanoma Progression and Drug Resistance through Down-Regulation of Bmi-1The American Journal of Pathology, 2012
- c-Myb and its target Bmi1 are required for p190BCR/ABL leukemogenesis in mouse and human cellsLeukemia, 2011
- Chondrocyte innate immune myeloid differentiation factor 88–dependent signaling drives procatabolic effects of the endogenous toll‐like receptor 2/toll‐like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in miceArthritis & Rheumatism, 2010
- Cell‐autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cellsThe Prostate, 2009
- Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cellsProceedings of the National Academy of Sciences, 2007
- Structure and E3‐ligase activity of the Ring–Ring complex of Polycomb proteins Bmi1 and Ring1bThe EMBO Journal, 2006
- Role of Bmi-1 and Ring1A in H2A Ubiquitylation and Hox Gene SilencingMolecular Cell, 2005
- The functions of animal microRNAsNature, 2004